Recursion

Join us today at 6:30am MT / 8:30am ET / 1:30pm GMT for our (L)earnings Call focused on our business updates and financial results for our fourth quarter and fiscal year ending December 31, 2024. Questions may be submitted at: https://bit.ly/40UiVkb

Maureen Makes, VP of Engineering and the site lead for Recursion’s London office, recently shared insights as part of Code to Cure: The London TechBio Revolution co-hosted by Relation and British Land. Alongside panelists Sergei Yakneen, CTO of Isomorphic Labs; Lindsay Edwards, CTO of Relation; Luke Timmerman, Founder of Timmerman Reports; and Nerida Scott, Head of Innovation, Johnson & Johnson, Maureen shared Recursion’s approach to automating novel discovery and rapidly generating new molecules. “We're generating these huge amounts of data in our wet lab up front – this phenomics data as well as transcriptomics data and proteomics data…to have this huge embedding space that can look at gene-gene, gene-compound interactions and across the entire genome,” she said.? ? Now, she adds: “We've really been focusing through our combination [with Exscientia] to be able to quickly say ‘OK, once we have a hit, how do we use our design platform to generate as few molecules as possible to be able to get that compound that can go to the clinic?’” Maureen will be presenting next at the AI in Drug Discovery conference in London March 10-11 with Karen Sayal, Senior Director in AI-Driven Industrialized Clinical Development. ??? Register here: https://bit.ly/3Eg0ZZz

“A series of ‘a-ha’s’ that lead to a big wow.” In an interview with Luke Timmerman of The Long Run podcast, Chief R&D and Chief Commercial Officer Najat Khan, PhD shares her journey, including obstacles she faced as an AI leader in pharma, and how she’s working to counter AI hype with transparency and 'a-ha' moments. Some highlights below: ?? Why she embraces the word “and”: “'And’ is always important? - connectivity and cross-silo efforts leads to the next level of insights.” At BCG, she says, she learned that she wanted to be the “person in the arena.” She left to become J&J’s Chief Data Science Officer and Global Head of Strategy & Portfolio Organization, where she was able to “combine disciplines and business acumen – taking her AI division from 5 people to 250” and managing R&D and portfolio strategy which allowed her to be “deep in the details.”? ?? Why she focused on clinical trials: “The time to value to show results is actually faster than in discovery. If you can actually design for the right patient, right study, doing monotherapy dose escalation, you can start to see it in a few months. If you can bring it to market 3 months earlier, 6 months earlier, before your competitor, the gains are obvious.” at J&J, she says: “I did that – scaled –?across 50 programs in the pipeline.” ?? Why there is no turning back: “We’ve been talking about this 10% success rate. I remember when I was in grad school, the cost of a drug was about a billion and now we say it’s upwards of $2.5 billion to $3-3.5 billion per drug – it is unsustainable. Patients are waiting.” ?? Why Recursion’s approach resonates: “We only understand about 10-15% of biology. A lot of the data that needs to be generated doesn’t exist. I was impressed with the wet-dry lab combination which is needed to not just run experiments but learn from it really fast and then predict what the next set of experiments need to be.” “The combination with Exscientia”, she adds, “took it to the next level. How do you build on developing molecules with AI in a fundamentally different way? Timelines are much shorter – designing 200 molecules to get to a lead candidate versus an industry that’s 2500 or more. That pivot that you need to make in terms of rich ideas that are coming from the biology platform and then adding to that the complementary chemistry platform – if you have both, then you really have a full stack AI-powered tech platform.”? ? ?? Listen to the full conversation here: https://lnkd.in/e2S7cXXt

?? Last week, in honor of Rare Disease Day, we welcomed rare disease patients, families, patient advocates, researchers, and physicians to join us at our Salt Lake City headquarters to share their stories. ?? Thank you to everyone who participated and helped to reaffirm our commitment to raising awareness around rare diseases and accelerating efforts to find a cure. ?? Learn more: https://rarediseases.org/ #rarediseaseday National Organization for Rare Disorders

Today, we announced business updates and financial results for our fourth quarter and fiscal year in 2024. It was a year marked by the largest business combination in TechBio – our combination deal with Exscientia – and significant advances across our platform, pipeline, and partnerships. Platform: The Recursion OS – our AI-powered platform spanning target discovery through clinical development – is enabling efficient molecule design and testing for both first and best-in-class opportunities. Highlights: ?? Integrating Exscientia’s precision chemistry platform into more than 10 design cycles for programs and mapping 1.4 million active ligands to binding pockets for structure-based drug discovery and target deconvolution. ?? Developing breakthroughs in multimodal foundation models.? ?? Advancing causal AI models and ClinTech – building a patient stratification framework for multiple programs. Pipeline: We presented promising early Phase 1/2 safety and efficacy results for REC-617, a potent, selective, oral CDK7 inhibitor for advanced solid tumors optimized through our AI platform. Our Phase 2 results for REC-994, a potential first-in-disease superoxide scavenger for symptomatic CCM, showed preliminary safety in chronic dosing as well as encouraging trends in efficacy. We initiated 3 new clinical studies:? ?? Phase 1/2 trial investigating REC-1245, a potential first-in-class RBM39 degrader, in biomarker-enriched advanced solid tumors and lymphoma. ?? Phase 1b/2 trial investigating REC-4881 for familial adenomatous polyposis (FAP). ?? Phase 2 trial investigating REC-3964, a potential first-in-class C. diff toxin B inhibitor, for preventing recurrent C. difficile infection. We received regulatory clearance to advance oncology trials for: REC-3565, a potential best-in-class MALT1 inhibitor and REC-4539, a potential best-in-class, CNS penetrant LSD1 inhibitor. We nominated REV102, a potential first-in-class ENPP1 inhibitor for hypophosphatasia ?in a joint venture with Rallybio as a development candidate and progressed REC-4209, a potential first-in-class therapy for idiopathic pulmonary fibrosis, to IND-enabling studies. Partnerships:? ?? The neuroscience phenomap work led to the exercise of a $30M option by Roche and Genentech in August 2024, and the collaboration is moving forward with target validation projects. ?? In 2024, two programs advanced through initial milestones, generating $15M in aggregate payments from Sanofi. ?? With Bayer, completed 25 multimodal oncology data packages with multiple programs rapidly progressing to Lead Series nomination. Read more: https://lnkd.in/geuN3AQT Today, Feb. 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30pm GMT, we will host a (L)earnings Call. Tune in on LinkedIn and: Twitter/X: https://lnkd.in/gn52iH5F? YouTube: https://lnkd.in/gNx66QJK Submit questions:? https://bit.ly/40UiVkb

In a new interview with PharmaVoice, Recursion CFO Ben Taylor discusses AI disruption in biopharma, what companies should be looking for in partnerships, and the challenges with a data-driven approach to shifting the industry. ?? On how AI is disrupting traditional drug discovery: “The right way to think about AI is as a far better tool than [what] has been available previously that gives you functionality that wasn’t there before…In biology and chemistry, there are no simple problems — everything is a complex, multi-parameter problem…You’re not going to solve all of the different aspects to create a new molecule with a single algorithm — you need to integrate them.” ?? On what’s required for successful TechBio-pharma partnerships: “If you think about the pharma decision making process…there are a lot of different signoffs. I can always tell the companies that are committed to AI because you see that smoothness of decision making, and that engagement comes from all levels inside the organization. If you don’t have that, getting the milestone across can be really tough, because it always requires another level of approval.” ?? On the importance of high quality data: “A lot of the data that has been collected historically generally isn’t in the right format or is very specific and not that useful. We use public datasets, or when we’re in a partnership we use their data and dig into everything we can, but honestly it only gets us to a very rough starting position. More useful is creating a fit-for-purpose dataset to be able to answer questions — and it’s fit directly for the purpose of the questions you’re asking.” ?? Read more: https://lnkd.in/d8guKicw #ai #pharma #drugdiscovery #techbio

?? As a National Organization for Rare Disorders of Rare Disorders corporate council member and sponsor of the Rare Disease Day awareness campaign, we’re committed to spreading awareness around rare diseases – including the patients and their families who are impacted, and the researchers and physicians who are working toward a cure.? ?? Today at our company All Hands we heard from a rare disease patient who has been able to manage his condition due to diagnosis and treatment and is currently completing his graduate studies at University of Utah as well as from Josh Bonkowsky, MD PhD, Chief, Division of Pediatric Neurology & Director, Primary Children's Center for Personalized Medicine at University of Utah, who is using rapid whole genome sequencing among other methods to help accelerate personalized treatments. ?? Tomorrow, Feb. 27, 4:30-7pm MT, in celebration of Rare Disease Day, we’re welcoming speakers from across Utah’s rare disease and health innovation community to share their stories. The event is available in person and online and is open to the public. ?? Speakers include: ?? Dr. Tracy George Unit and Chief Scientific Officer, ARUP Laboratories & Professor of Pathology, Spencer Fox Eccles School of Medicine, University of Utah ?? Aimee Edwards, Executive Director, BioHive Utah ?? Kelvyn Cullimore, President & CEO, BioUtah ?? Sylvia Lam, Advocate, Utah Rare Disease Advisory Council (RDAC) ?? Ava Szajnuk, Undiagnosed Rare Disease Patient, Rare and Undiagnosed Network (RUN) ?? Rachel Palmquist, University of Utah Health, Intermountain Genetic Counselor, Primary Children’s Gene Kids ?? Stacey L. Clardy, MD PhD FAAN, MD PhD, Associate Professor of Neurology, University of Utah & Salt Lake City VAMC Recursion Co-founder and CEO Chris Gibson will open the event, and Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will provide closing remarks. Join us! ? Details and registration here: https://lu.ma/itz526zb #rarediseaseday

“The future of American health care innovation is hanging in the balance.” In an op-ed in STAT, Recursion co-founder and CEO Chris Gibson discusses the recent policy changes that have added uncertainty to critical funding paths, including the NIH Small Business Innovative Research (SBIR) program – and why it’s time for industry to step up. Around 1,500 health care-related startups with SBIR funding are now in limbo, Chris writes. “These companies — many of which could be the next great American medical breakthrough — now face an uncertain future because they are stuck between halted funding and a lack of private investment.” He shares how these recent policy changes drove him to establish a new pre-seed venture fund – the Altitude Lab Fund – for early-stage startups impacted by SBIR funding freezes, and he calls on others to do the same, writing: “Those of us in the industry with the resources to help should step up to help keep the money going for the next generation of innovators.” Read in full ??

??? Join us at the AI in Drug Discovery conference in London March 10-11. ? The conference will showcase how AI-driven technologies are being applied to end-to-end drug discovery and development, including data generation, target identification, computational drug design, R&D efficiency, and optimizing clinical trials. ? Maureen Makes, VP of Engineering and site lead for Recursion’s London office, is chairing the conference on March 11, providing opening and closing remarks. ? Karen Sayal, Senior Director in AI-Driven Industrialized Clinical Development, will present March 11 on “AI-Driven Optimization of Clinical Trials” sharing insights into the use of agentic systems for clinical trials and the guiding principles for real-world deployment within evolving compliance frameworks. ?? Where? London, UK ??? When? March 10-11, 2025 ??? Register here: https://bit.ly/3Eg0ZZz #AIinDrugDiscovery

Recursion was thrilled to be part of the recent BioHive Utah Live event -- celebrating the innovators and business leaders who are working to elevate Utah's healthcare and life sciences industry. ?? Special congratulations to: ?? Katherine Matsumoto, PhD, Recursion's Communications and Culture Fellow, who was named Storyteller of the Year. Katherine is passionate about the intersection of culture, communication, and technology, and is known for her ability to develop innovative strategies that foster a collaborative and inclusive workplace. ?? Altitude Lab, Recursion's healthcare accelerator in Utah led by executive director Chandana Haque, which supports diverse life science entrepreneurs in?Utah?by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community. #BioHiveLive #BestofBioHive #BioHiveWeek BioHiveLive.com